Alfred Moon, MD
Allergy & Immunology · Yorba Linda, CANPI 1396953105
Payments from drug & device makers
Across 465 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Amgen$986
- Regeneron Healthcare Solutions, Inc.$957
- AstraZeneca$938
- Pfizer$824
- Takeda Pharmaceuticals U.S.A., Inc.$818
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,00299%
- Education$1251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 81 | $1,035 |
| Amgen | 40 | $986 |
| Regeneron Healthcare Solutions, Inc. | 40 | $957 |
| AstraZeneca(2 entities) | 28 | $938 |
| Pfizer | 53 | $824 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $818 |
| Sanofi | 44 | $783 |
| Optinose US, Inc. | 25 | $520 |
| Biocryst US Sales Co., LLC | 9 | $238 |
| CSL Behring | 6 | $206 |
| Novartis | 11 | $180 |
| Shire North American Group Inc | 12 | $162 |
| Genentech USA, Inc. | 7 | $155 |
| Aimmune Therapeutics, Inc. | 2 | $140 |
| Kaleo, Inc. | 7 | $138 |
| Kyowa Kirin, Inc. | 1 | $113 |
| Pharming Healthcare, Inc. | 5 | $108 |
| Cycle Pharmaceuticals Inc | 1 | $100 |
| Incyte Corporation | 4 | $92 |
| Alk-abello, Inc | 2 | $87 |
| Grifols USA, LLC | 3 | $81 |
| Novo Nordisk | 4 | $81 |
| Ionis Pharmaceuticals, Inc. | 2 | $49 |
| Bausch Health US, LLC | 2 | $45 |
| Genentech, Inc. | 2 | $39 |
| Merck | 2 | $36 |
| Greer Laboratories, Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| AbbVie | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,127 in reported general payments places this provider in the 70th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $578,430 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $200,749 |
| Dupixent PenDupilumab | 24 | $136,375 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 29 | $136,180 |
| TezspireTezepelumab-Ekko | 26 | $114,308 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $63,495 |
| XolairOmalizumab | 12 | $56,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $45,049 |
| Epinephrine | 27 | $4,588 |
| Azelastine Hcl | 124 | $3,524 |
| DuleraMometasone/Formoterol | 11 | $3,406 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,610 |
| Clemastine Fumarate | 13 | $2,482 |
| Ipratropium Bromide | 85 | $2,462 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 14 | $2,393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro, Cuvitru, Gammagard Liquid | $818 | $915,35869 claims |
| AstraZenecaTezspire | $938 | $114,30826 claims |
| Grifols USA, LLCGamunex-C | $81 | $63,49520 claims |
| Genentech, Inc.Xolair | $39 | $56,54012 claims |
| GSKTrelegy Ellipta | $1,035 | $45,04944 claims |
| MerckDulera | $36 | $3,40611 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $100 | $1,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Yorba Linda
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
- James WolfeSan Jose$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.